[go: up one dir, main page]

DE60101201D1 - Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca - Google Patents

Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Info

Publication number
DE60101201D1
DE60101201D1 DE60101201T DE60101201T DE60101201D1 DE 60101201 D1 DE60101201 D1 DE 60101201D1 DE 60101201 T DE60101201 T DE 60101201T DE 60101201 T DE60101201 T DE 60101201T DE 60101201 D1 DE60101201 D1 DE 60101201D1
Authority
DE
Germany
Prior art keywords
nicotinergen
medicament
manufacture
treatment
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60101201T
Other languages
English (en)
Inventor
R Yerxa
M Peterson
Mathew Cowlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60101201D1 publication Critical patent/DE60101201D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
DE60101201T 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca Expired - Lifetime DE60101201D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
DE60101201D1 true DE60101201D1 (de) 2003-12-18

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60101201T Expired - Lifetime DE60101201D1 (de) 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Country Status (8)

Country Link
US (1) US6277855B1 (de)
EP (1) EP1214062B1 (de)
JP (1) JP2003531168A (de)
AR (1) AR028026A1 (de)
AT (1) ATE253912T1 (de)
AU (1) AU2001253765A1 (de)
DE (1) DE60101201D1 (de)
WO (1) WO2001080844A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
WO2004012674A2 (en) * 2002-08-02 2004-02-12 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2004037167A2 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
CN100430066C (zh) * 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
EP1591110B1 (de) * 2003-01-22 2015-03-18 Senju Pharmaceutical Co., Ltd. Perkutanes absorptionspräparat zur behandlung von augenerkrankungen, seine verwendung und verfahren zur migration des augenpräparats in das topische gewebe eines auges
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
WO2005060984A1 (en) * 2003-12-12 2005-07-07 Yee Richard W Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2005115432A2 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US20070053964A1 (en) * 2004-05-21 2007-03-08 Akiharu Isowaki Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
JP4932480B2 (ja) 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
EP1765075A4 (de) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
JPWO2007013661A1 (ja) * 2005-07-26 2009-02-12 千寿製薬株式会社 眼科用経皮吸収型製剤
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8182841B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
BRPI0912679A2 (pt) * 2008-05-16 2016-01-26 Axis Inc composição farmacêutica para o tratamento de fibromialgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
MX2011003306A (es) * 2008-10-14 2011-09-01 Psychogenics Inc Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
AU2010213244A1 (en) * 2009-02-11 2010-08-19 Heglund, A.S. A composition for buccal absorption of nicotine for the purpose of smoking cessation
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
EP2665741B1 (de) * 2011-01-10 2019-03-06 Invion, Inc Verwendung von betaadrenergen inversen agonisten zur raucherentwöhnung
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9931423B2 (en) 2011-08-26 2018-04-03 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) * 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
US9265956B2 (en) 2013-03-08 2016-02-23 Oculeve, Inc. Devices and methods for treating dry eye in animals
WO2014165124A1 (en) 2013-03-12 2014-10-09 Oculeve, Inc. Implant delivery devices, systems, and methods
WO2014172693A2 (en) 2013-04-19 2014-10-23 Oculeve, Inc. Nasal stimulation devices and methods
AU2015223184B2 (en) 2014-02-25 2020-07-02 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
AU2015292278B2 (en) 2014-07-25 2020-04-09 Oculeve, Inc. Stimulation patterns for treating dry eye
PT3848028T (pt) 2014-10-20 2024-09-20 Oyster Point Pharma Inc Métodos de tratamento de estados oculares
EP3209371A4 (de) 2014-10-22 2018-10-24 Oculeve, Inc. Implantierbare nasenstimulatorsysteme und verfahren
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
MX2017005204A (es) 2014-10-22 2017-12-14 Oculeve Inc Dispositivos y métodos de estimulación para tratar el ojo seco.
CA2964163A1 (en) * 2014-11-05 2016-05-12 Tissuetech, Inc. Compositions and method for promoting nerve growth and regeneration
AU2015374033B2 (en) 2014-12-31 2020-07-02 Microoptx Inc. Glaucoma treatment devices and methods
WO2016184998A1 (fr) * 2015-05-21 2016-11-24 Ophtalmis Monaco Association d'acide lipoique et de taurine en tant qu'agent osmoprotecteur
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
US10980667B2 (en) 2015-09-30 2021-04-20 Microoptx Inc. Eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
PT3439661T (pt) * 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
CA3014725C (en) 2016-04-12 2020-09-22 Arturo Solis Herrera Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
JP2020500609A (ja) 2016-12-02 2020-01-16 オキュリーブ， インコーポレイテッド ドライアイ予測及び治療勧告のための装置及び方法
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
TW202317111A (zh) * 2021-07-07 2023-05-01 坎培拉大學 治療及抑制方法
DE102023208057A1 (de) 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
JP3034953B2 (ja) 1992-08-31 2000-04-17 ユニバーシティー オブ フロリダ リサーチ ファンデーション，インコーポレーテッド 神経系の変性疾患の治療に有用なアナバセイン誘導体
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
WO2001080844A3 (en) 2002-03-28
AR028026A1 (es) 2003-04-23
ATE253912T1 (de) 2003-11-15
WO2001080844A2 (en) 2001-11-01
EP1214062B1 (de) 2003-11-12
AU2001253765A1 (en) 2001-11-07
JP2003531168A (ja) 2003-10-21
US6277855B1 (en) 2001-08-21
EP1214062A2 (de) 2002-06-19

Similar Documents

Publication Publication Date Title
DE60101201D1 (de) Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60026704D1 (de) (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE50014699D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
DE60138129D1 (de) Apparat zur behandlung von zähnen
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60115874D1 (de) Instrument zur chirurgischen behandlung
MXPA03001789A (es) Composiciones para el cuidado de telas que comprenden silicones cationicos y metodos que emplean las mismas.
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60012138D1 (de) Gerät zur behandlung von fibrillation

Legal Events

Date Code Title Description
8332 No legal effect for de